Opthea Ltd (CKDXF) stock
CKDXFOTCBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as CYVNY
$0.01+0.00 (0.00%)
Close on Oct 19, 2026Market cap –P/E –Yield –
Opthea r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $126.83M, down 28.1% from the year before. The highest annual figure on record is $176.33M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $126.83M | -28.1% |
| FY2024 | Jun 30, 2024 | $176.33M | +36.9% |
| FY2023 | Jun 30, 2023 | $128.83M | +58.2% |
| FY2022 | Jun 30, 2022 | $81.45M | +214.6% |
| FY2021 | Jun 30, 2021 | $25.89M | +114.6% |
| FY2020 | Jun 30, 2020 | $12.06M | -46.2% |
| FY2019 | Jun 30, 2019 | $22.42M | – |
See a number that looks wrong?